Akebia Therapeutics, Inc.
AKBA
$1.65
$0.106.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -17.26% | -10.98% | -22.58% | -18.49% | 0.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.26% | -10.98% | -22.58% | -18.49% | 0.74% |
| Cost of Revenue | -9.02% | -39.98% | -4.60% | -76.21% | 121.37% |
| Gross Profit | -18.82% | -2.10% | -26.09% | 4.54% | -51.56% |
| SG&A Expenses | 8.80% | 16.76% | -0.44% | 1.54% | -14.95% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.30% | -9.07% | -20.00% | -28.03% | 82.18% |
| Operating Income | -441.88% | 2.81% | 4.02% | 43.20% | -88.88% |
| Income Before Tax | -3,814.01% | -38.30% | 23.18% | 33.08% | 110.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3,814.01% | -38.30% | 23.18% | 33.08% | 110.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,814.01% | -38.30% | 23.18% | 33.08% | 110.11% |
| EBIT | -441.88% | 2.81% | 4.02% | 43.20% | -88.88% |
| EBITDA | -106.10% | 9.51% | 116.09% | 68.80% | -65.65% |
| EPS Basic | -3,359.38% | -23.93% | 31.61% | 39.66% | 109.70% |
| Normalized Basic EPS | -837.50% | -25.26% | 28.69% | 42.62% | -91.64% |
| EPS Diluted | -3,359.38% | -23.93% | 31.61% | 39.66% | 108.53% |
| Normalized Diluted EPS | -837.50% | -25.26% | 28.69% | 42.62% | -91.64% |
| Average Basic Shares Outstanding | 15.16% | 11.71% | 12.25% | 10.93% | 3.21% |
| Average Diluted Shares Outstanding | 14.80% | 11.71% | 12.25% | 10.93% | 3.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
